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 Radiolabeling process of monoclonal antibodies with 99mTc 
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The use of monoclonal antibodies (Mab) in the current medicine is increasing. 
Antibody-drug conjugates (ADCs) represents an increasingly and important modality 
for treating several types of cancer. In this area, the use of Mab associated with 
nanoparticles is a valuable strategy. However, the methodology used to calculate the 
Mab entrapment, efficiency and content is extremely expensive. In this study we 
developed and tested a novel very simple one-step methodology to calculate 
monoclonal antibody entrapment in mesoporous silica (with magnetic core) 
nanoparticles using the radiolabeling process as primary methodology. The magnetic 
core mesoporous silica were successfully developed and characterized. The  PXRD 
analysis at high angles confirmed the presence of magnetic cores in the structures 
and transmission electron microscopy allowed to determine structures size (58.9 ± 
8.1 nm). From the isotherm curve, a specific surface area of 872 m2/g was estimated 
along with a pore volume of 0.85 cm3/g and an average pore diameter of 3.15 nm. 
The radiolabeling process to proceed the indirect determination were well-done. 
Trastuzumab were successfully labelled (>97%) with Tc-99m generating a clear 
suspension. Besides, almost all the Tc-99m used (labelling the trastuzumab) 
remained trapped in the surface of the mesoporous silica for a period as long as 8 
hours. The indirect methodology demonstrated a high entrapment in magnetic core 
mesoporous silica surface of Tc-99m-traztuzumab. The results confirmed the 
potential use from the indirect entrapment efficiency methodology using the 
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 The use of monoclonal antibodies (Mabs) in the current medicine is 
increasing each day. Monoclonal antibody-based treatment is used in a great 
variety of disease, with especial attention in oncology [1-3] 
 
Antibody-drug conjugates (ADCs) are monoclonal antibodies attached to 
biologically active drugs by chemical linkers with labile bonds. It represents an 
increasingly and important modality for treating several types of cancer. The 
impact of ADCs in this field is due the exquisite specificity of antibodies that 
deliver the conjugated cytotoxic agent to targeted tumor cells, thus reducing the 
systemic toxicity associated with traditional chemotherapeutic treatments. ADCs 
are distinguished on the basis of the drug, linker, and also the amino acid 
residue of attachment on the antibody [4-6]. In the field of ADC, the use of Mab 
associated with nanoparticles is very common [7-9]. In this specific ADC case 
the calculation of Mab entrapment efficiency is of vital importance and in many 
cases requires a specific and expensive methodology.   
 
The primary method to evaluate the mAb purification can be made by 
Protein A chromatography, followed by two or three subsequent 
chromatographic polishing steps [10]. In this case the chromatographic column 













through development of higher capacity resins and use of mixed-mode 
sorbents. Another methodology involves mass spectroscopy or mass 
spectroscopy-associated liquid chromatography [11,12]. In both cases, the 
methodology used to calculate the Mab entrapment, efficiency and content is 
extremely expensive. In this study we developed and tested a novel and very 
simple one-step methodology to calculate monoclonal antibody entrapment 
efficiency in mesoporous silica nanoparticles using the radiolabeling process as 
primary methodology.  
 
 
2. Materials and methods 
2.1. Preparation of magnetic core mesoporous silica nanoparticles 
(MSN) 
 
2.1.1. Reagents and materials 
Iron(III)chloride hexahydrate, iron(II)tetrachloride hexahydrate, oleic acid, 
hexadecyltrimethylammonium bromide (CTAB) and tetraethyl orthosilicate 
(TEOS) were purchased form Sigma. Ammonia solution (32%), ethanol and 
ethyl acetate were purchased from Scharlau. Chloroform was obtained from 
Acros Organics. Distilled water was used in all reactions. 
 
2.1.2. Synthesis of oleate-coated iron oxide nanoparticles  
Iron oxide nanoparticles (Fe3O4 magnetite nanocrystals) were obtained by a 
modified coprecipitation method [1]. Briefly, 12 g of iron(III)chloride hexahydrate 













under a flow of argon and mechanical stirring. Ammonia solution 32% (19.53 
ml) was carefully added and the mixture turned completely dark. Oleic acid 
(2.13 ml) was added after 30 min and the reaction was left stirring at 80 ºC for 
another 90 min. The reaction was cooled down and centrifuged at 9500 rpm for 
10 min. The resulting black precipitate was washed three times with distilled 
water and three times with ethanol and then dried under vacuum overnight. In 
order to prevent their oxidation, the oleate-coated iron oxide nanoparticles were 
kept in chloroform giving a dark brown ferrofluid. 
 
2.1.3. Synthesis of magnetic core MSNs 
In a typical procedure, 100 mg of CTAB were dissolved in 10 ml of water, 
followed by addition of 0.74 ml of the ferrofluid (8.88 mg/ml). The mixture was 
placed in a probe sonicator (Branson 450 Sonifier) for 2 min, giving an oil-in-
water emulsion. Then, the mixture was heated to 65 ºC to evaporate the 
chloroform and achieve an effective phase transfer from chloroform to water. 
The resulting transparent aqueous suspension was added to a solution of 30 ml 
of water and 0.548 ml of ammonia (32%), which was then, heated up to 75 ºC. 
Then, 0.5 ml of tetraethyl orthosilicate (TEOS) was added dropwise followed by 
addition of 3 ml of ethyl acetate. The reaction was stirred at 350 rpm and 75 ºC 
during 3 h. Then, the reaction mixture was placed on an ice bath and the 
nanoparticles were collected by centrifugation (9500 rpm, 10 min). Afterward, 
the sample was washed with ethanol twice and dried under vacuum overnight. 
The final magnetic core MSNs were calcined in air at 550 ºC for 5 h. 
 













2.2.1. Powder X-ray diffraction 
The synthesised materials were characterised by powder X-ray diffraction 
(PXRD), transmission electron microscopy (TEM) and N2 adsorption-desorption 
analysis. PXRD measurements were obtained using a Bruker AXS D8 Advance 
diffractometer equipped with CuKα radiation and working at 40 kV/40 mA. 
PXRD measurements were performed at high angle (2θ = 15°- 68°) and low 
angle range (2θ = 1.3°- 8.3°). 
 
2.2.2. Transmission electron microscopy 
TEM images were taken on a 100 kV JEOL JEM-1010 microscope operated 
with AMT image capture engine software. TEM samples were prepared by 
adding 10 µl of nanoparticles suspended in distilled water onto carbon-coated 
copper grids. The statistical analysis of the data obtained from TEM images was 
performed using Origin Pro software. 
 
2.2.3. N2 adsorption-desorption 
N2 adsorption-desorption measurements were conducted in a TriStar II Plus 
surface area and porosity analyzer from Micromeritics. The specific surface 
area of the material was determined from the adsorption-desorption isotherm by 
applying the BET (Brunauer-Emmett-Teller) model. The pore volume and 
average pore size was estimated by using the BJH (Barrett-Joyner-Halenda) 
model. 
 














Magnetic core mesoporous silica nanoparticles were loaded with 
trastuzumab. In order to get the loaded magnetic core mesoporous silica 
nanoparticles, 200 µg (200 µg/1 mL) of Herceptin® (trastuzumab) was stirred 
(24 hrs) at room temperature with 100 µg of magnetic core mesoporous silica 
nanoparticles. After this period the magnetic core mesoporous silica 
nanoparticles soaked with trastuzumab solution was dried under low pressure 
at 30şC temperature for 12 hours, until completely dry. The dried powder 
containing solely magnetic core mesoporous silica nanoparticles loaded with 
trastuzumab were individualized and set aside for later labeling with Tc-99m. 
The calculation to determine the amount of trastuzumab necessary to complete 
dope the magnetic core mesoporous silica nanoparticles was done considering 
the size of the magnetic core mesoporous silica nanoparticles (100 nm) applied 
to the circumference volume (Cv) equation (1): 
Equation 1:  
Where: Cv: circumference volume 
: constant  
R: Radius of the circumference 
 
In this case, we have that the weight of one single magnetic core 
mesoporous silica nanoparticle is about: 1x10-15 g. Thus, in 100 µg of magnetic 
core mesoporous silica nanoparticles we have approximately 1012-13 
nanoparticles with a surface area approximately 872 m2/g. This means that 
using an excess of Mab (200 µg) that has a molar mass of 145.531,5 g mol-1 we 














2.4. Trastuzumab labeling process with Tc-99m 
The labeling process was done by the direct radiolabeling process as 
described previously by Pascual et al. [13], Cerqueira-Coutinho et al. [14] and 
Rosa et al. [15]. In this methodology we used 150 µg of trastuzumab. Briefly, 
100 µCi (approximately 300 µL) of Tc-99m was incubated with a stannous 
chloride (SnCl2) solutions (80 µg/mL) (Sigma-Aldrich) for 20 minutes at room 
temperature. Then this solution was incubated with 150 µg trastuzumab for 
another 10 minutes in order to label their structures. 
 
2.5. Quality control of the labeling process with Tc-99m 
In order to confirm the efficiency of the trastuzumab labeling process, 
paper chromatography was done using Whatman paper nº 1 using 2 l of the 
labeled-nanoparticle and acetone (Sigma-Aldrich) as mobile phase. The 
radioactivity of the strips was verified in a γ-counter (Perkin Elmer Wizard® 
2470, Shelton, CT City, State). 
 
2.6.  Indirect entrapment efficiency calculation – Tc-99m EE% 
To perform the entrapment efficiency of the trastuzumab into the 
magnetic core mesoporous silica nanoparticles we performed the Tc-99m 
entrapment efficiency. In this direction, we previously labeled the trastuzumab 
with Tc-99m and then, doped the magnetic core mesoporous silica 
nanoparticles as described in the section: doping magnetic core mesoporous 
silica nanoparticles with radiolabeled trastuzumab (Tc-99m-trastuzumab). 
 













Planar images from the chromatographic system using Tc-99m-
trastuzumab (3.7 MBq in 0.2 mL) were done in triplicate. The images were 
integrated for 5 min centered at 140 KeV, with a Millennium Gamma Camera 
(GE Healthcare, Cleveland, USA), using a 15% window. The images were 
processed using OsiriX software. 
 
3. Statistical analysis 
 Statistical analyses were performed using Origin Pro 8 (OriginLab, USA) 
software. Results are shown as means ± standard deviation (S.D.). P-values 
less than 0.05 were considered significant. 
 
4. Results and discussion 
4.1. Characterization of magnetic core MSNs  
The structure periodicity of the mesoporous material was confirmed by PXRD, 
which showed a sharp peak at the low-angle region for both as-made (S0-1) 
and calcined (S0-2) magnetic core MSNs (Figure 1). The slight shift of the peak 
to higher angles indicates shrinkage of the silica matrix due to the condensation 
of silanol groups during the calcination process. PXRD analysis at high angles 
confirmed the presence of magnetic cores within the structure (see inset in 
Figure 1). 
 
The mesoporous structure of S0-2 magnetic core MSNs was also analysed by 
transmission electron microscopy and the size of the primary nanoparticles was 













represented in a histogram, which shows the particle size distribution of the S0-
2 nanoparticles (Figure 2 A and B).  
 
The N2 adsorption-desorption isotherms of the magnetic core MSNs presented 
a typical type IV behaviour (Figure 3), characteristic of mesoporous materials. 
From the isotherm curve, a specific surface area of 872 m2/g was estimated 
along with a pore volume of 0.85 cm3/g and an average pore diameter of 3.15 
nm. 
 
4.2. Trastuzumab labeling process with Tc-99m 
The trastuzumab were successfully labelled (>97%) with Tc-99m generating a 
clear suspension. 
 
4.3. Quality control of the labeling process with Tc-99m 
The effectiveness of the labeling process was confirmed by paper 
chromatography which indicated almost no significant dissociation of 
technetium-99m from the trastuzumab for a period as long as 8 hours, as 




















In order to corroborate the paper chromatography a planar imaging from the 
paper chromatographic system has been performed, as shown in Figure 4. 
 
 
The results showed an ascending movement with a great amount in the base 
corroborating the formation of the complex between the Tc-99m and the 
trastuzumab.  
 
4.5. Entrapment efficiency – Tc-99m EE% 
In order to calculate the amount of Tc-99m that has been absorbed/doped into 
the magnetic core mesoporous silica nanoparticles (together with the trastuzumab) 
we calculated the entrapment efficiency (EE%) of Tc-99m-trastuzumab into the 





The result found for the Tc-99m EE% was 97,5% ±0,8. This result confirmed 
that almost all the Tc-99m used (labelling the trastuzumab) was trapped in the 
surface of the mesoporous silica. 
The quality control of the solely trastuzumab labeling process with Tc-99m 













period as long as 8 hours ( as shown in Table 2), corroborating our decision to use 




The results confirmed the potential use from the indirect entrapment 
efficiency methodology using the radiolabeling process. This methodology 
although involves the use of radioactive material can be an easy, rapid and 
efficient methodology that can be used to calculate Mab adsorption/entrapment 
efficiency into nanoparticles systems. 
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Figure 1. Powder X-ray diffraction patterns of (bottom) as-made magnetic core 
MSNs (S0-1) and calcined magnetic core MSNs (S0-2). Inset shows the peaks 
corresponding to magnetite nanocrystals and the characteristic broad peak of 
amorphous silica. 
 
Figure 2. A: Transmission electron microscopy images of calcined S0-2 
nanoparticles, showing the spherical shape and the magnetic core . B: 
Histogram and normal size distribution of calcined S0-2 nanoparticles 















Figure 3. N2 adsorption-desorption isotherm of calcined S0-2 nanoparticles. 
Inset shows the pore size distribution of the material. 
 
Figure 4. Planar imaging from the chromatographic system corroborating the 
















Table 1. Percentage of labeled trastuzumab observed over time, after 
ascending chromatograms of Tc-99m compared with free pertechnetate (NaTc-
99mO4–). 
 
Time (h) Labeling (%)Trastuzumab 
0 98.6± 0.7% 
1 97.8± 0.5% 
2 97.3± 1.0% 
4 97.0± 0.8% 
8 97.1± 0.5% 
Table 2: Percentage of labeled trastuzumab observed over time, after 






0 99.1 ± 0.4% 
1 98.7 ± 0.9% 
2 97.9 ± 0.8% 
4 98.4 ± 1.1% 
8 97.5 ± 0.5% 
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